ICON plc | Clinical Research Organisation (CRO) for Drug Development

Patient centricity in orphan drug development

Patient involvement in the development of drugs for rare diseases.

ICER’s impact on payer decision making

Results of ICON’s third annual survey.

Mitigating the impact of COVID-19 on cardiovascular trials

Ensure patient safety and trial integrity during a global pandemic.

Dynamics of patient centricity in clinical research

Exploring the patient dynamic from different perspectives.

Featured Services

COVID-19 clinical operations

Keeping your clinical trial on track in an evolving environment.

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Biosimilars

ICON can support product design, development and registration, regulatory support and commercialisation of Biosimilars.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

08 April 2021

Looking back and looking ahead: Trends in HEOR

In-person research became impossible due to the pandemic, and forced us to re-examine how patient's voices were being captured. In 2021 we continue to build on what we learned.

06 April 2021

Navigating complexity of cell therapy manufacturing during the COVID-19 pandemic

Over the past year, the COVID-19 pandemic significantly disrupted clinical research across the lifecycle including recruitment challenges, protocol amendments and delayed market entry.

05 April 2021

Navigating complexity in oncology cell and gene therapy clinical trials

As more knowledge is revealed about the genetic underpinnings of cancers, cell and gene therapies (CGT) are playing an increasingly important role in treating oncology patients

01 April 2021

Innovation in oncology drug development: A focus on patient benefits

Improved diagnostic technologies, prevention methods and the advent of targeted therapeutic approaches have together contributed to lowering the mortality rate for the 10 most prevalent cancers

29 March 2021

Cell and gene therapy trials - delivering differently

The success of cell and gene therapies (CGT) has transformed the delivery of clinical trial services, requiring the design of new workflows, processes and tools.

24 March 2021

Multidiagnostic approaches for patient selection biomarkers in immuno-oncology

Advances in our understanding of cancer biology and the tumour microenvironment (TME), have led to the development of personalised drug and therapy designs to better prevent disease progression and relapse.

22 March 2021

Briefing: The UK NICE methods of health technology assessment

In a statement on February 2021, the UK’s National Institute for Health and Care Excellence (NICE) launched a public consultation on proposals for changes to the processes it uses to develop its guidance on medicines, medical devices, diagnostics and digital health technologies.

27 February 2021

Sharing my rare disease story - Hayley Christensen

ICON's Hayley Christensen shares her personal experience with Cystic Fibrosis.

27 February 2021

Sharing my rare disease story - Tamie Joeckel

ICON's Tamie Joeckel shares her personal experience with Type 3 Hereditary Angioedema.

サービス

Sectors

治療領域

イノベーション

業界を見通すインサイト

ニュース & イベント

アイコンについて

ICON to acquire PRA Health Sciences

Cell and Gene Therapy clinical trials

The evolution of HIV treatments

The IVDR journey